Aurobindo Pharma owner

If you want to know who really controls Aurobindo Pharma Limited (Aurobindo Pharma is a pretty big company. Aurobindo Pharma was founded in 1986 by Mr. P. V. Ramaprasad Reddy and Mr. K. Nityananda Reddy. The company commenced operations in 1988-89 with a single unit manufacturing semi-synthetic Aurobindo Pharma features among the top 10 companies in India in terms of consolidated revenues.In 2014, Aurobindo purchased the generic operations of Aurobindo Pharma plans to expand its product portfolio with high value products in In 2017, Aurobindo Pharma inked a pact to acquire Portugal’s Generis Farmaceutica SA from Magnum Capital Partners for a consideration of €135 million.Aurobindo Pharma Ltd. signed a definitive agreement to purchase the Apotex businesses in Poland, the Czech Republic, the Netherlands, Spain and Belgium. He had rendered his services as the non executive chairman of the Aurobindo Pharma Limited since 2012, November 30. This will allow investors to reduce the impact of non-fundamental factors, such as volatile block trading impact on their portfolio value. Start a 14-day free trial to Morningstar Premium to unlock the trailing 2-year trend of ownership. Insiders own ₹40b worth of shares in the ₹258b company. Insider Ownership Of Aurobindo Pharma The definition of an insider can differ slightly between different countries, but members of the board of … It was incorporated on 26 December, 1986 and is located in Andhra Pradesh, Telangana. The remaining stake is held by Gurunath Reddy and family, who are the company’s original promoters.GDPL, a 100 percent step-down subsidiary of IHH Healthcare, bought a 51 percent stake in Continental Hospitals in March 2015 by infusing equity of Rs 188.3 crore.Continental Hospital has a land area of 2.95 acres and built-up area of 1.3 million square feet located in the prime location of Gachibowli, Hyderabad.Currently, the multi-specialty hospital has a capacity for 300 beds, and has license to expand up to 750 beds capacity.Continental Hospitals has been a difficult experience for IHH Healthcare since it bought the stake in 2015.Differences cropped up between Gurunath Reddy, the original promoter and the Parkway management, within no time.Reddy is said to have developed grouse against Parkway for sidelining him and his team in the matters of running the hospital.The matters hit the nadir in May 2017, when Parkway allotted itself an additional 1.3 per cent shares, while increasing its stake to 52.3 percent and diluting other shareholders holding to 47.7 per cent. Every investor in Aurobindo Pharma Limited (NSE:AUROPHARMA) should be aware of the most powerful shareholder groups. The agreement is conditional on the receipt of competition clearances for the transaction by the Dutch and Polish authorities. It is classified as a public limited company.The company has ten directors - Govindarajan Narayanan, Ragunathan Kannan, and others. Taking a look at our data on the ownership groups (below), it's seems that institutional investors have bought into the company. AUROPHARMA’s considerably high level of institutional ownership calls for further analysis into its margin of safety. This can be negative in some circumstances.Our information suggests that insiders maintain a significant holding in Aurobindo Pharma Limited. Copyright © e-Eighteen.com Ltd. All rights reserved. Management ultimately answers to the board. Its marketing partners include Ast… HYDERABAD: Soon, the 108 ambulance services might be handled by Aurobindo Pharma Foundation, said highly placed sources from within the Telangana health department. Normally institutions would own a significant portion of a company this size. Warren Buffett said that he likes ‘a business with enduring competitive advantages that is run by able and owner-oriented people’. ownership structure should not be the only focus of your research when constructing an investment thesis around AUROPHARMA.

Reproduction of news articles, photos, videos or any other content in whole or in part in any form East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Midodrine Hydrochloride Tablets USP, 2.5 mg, 5 mg, and 10 mg. Aurobindo’s Midodrine Hydrochloride Tablets USP, 2.5 mg, 5 mg, and 10 mg, are an AB-rated generic equivalent to the reference listed drug (RLD), ProAmatine Tablets In potential litigation with the previous owner of Natrol Inc, Aurobindo Pharma's US affiliate has accused Plethico Pharmaceuticals of committing financial fraud with its previous step-down subsidiary, according to a report carried by Dow Jones Daily Bankruptcy Review on Monday. Our research team consists of equity analysts with a public, market-beating track record. The company’s area of activity includes six major therapeutic/product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. That's quite meaningful. Institutions often own shares in more established companies, while it’s not unusual to see insiders own a fair bit of smaller companies.

We would expect most companies to have some institutions on the register, especially if they are growing.We can see that Aurobindo Pharma does have institutional investors; and they hold 25% of the stock. East Windsor, NJ 08520-1401 (732) 839-9400.

You can The general public, with a 23% stake in the company, will not easily be ignored. In this article, I’m going to take a look at Aurobindo Pharma Limited’s ( It has a market capitalization of ₹258b. Ownership structure of a company has been found to affect share performance over time.

Of course, the future is what really matters.Hedge funds don't have many shares in Aurobindo Pharma. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast.